El medicamento para el cáncer de Novartis se aprobó con un precio de US$475.000

The transcript discusses CAR T therapy, a pioneering cancer treatment and the first gene therapy approved in the US. It highlights Gilead's acquisition of Kite Pharma and the potential approval of another CAR T drug. The discussion also covers the high cost of these therapies, with expectations that prices may decrease as usage increases and competition grows.

What are the expectations for future Carty therapies based on the current developments?

What is the significance of the first gene therapy approved in the US?

What are the potential implications of the price tag of $500,000 for the new cancer therapy?

What factors could lead to a decrease in the price of cancer therapies in the future?

How might the approval of more gene therapies affect the market price of these treatments?